DOCON TECHNOLOGIES PRIVATE LIMITED

Annexure-II

Format for disclosure by the Promoter(s) to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/ release of encumbrance, in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Thyrocare Technologies Limited ("Thyrocare")
Names of the stock exchanges where the shares of the target company are listed	1. BSE Limited 2. National Stock Exchange of India Limited
Date of reporting	August 17, 2026
Name of the promoter or PAC on whose shares encumbrance has been created/released/invoked	**Promoter**: Docon Technologies Private Limited **PAC**: API Holdings Limited
Details of the creation of encumbrance*	

Name of the promoter(s) PACs with him*	**Promoter holding in the target company (1)**		**Promoter holding already encumbered (2)**		**Details of events pertaining to encumbrance (3)**							**Post event holding of Encumbered shares {~~creation~~ [(2)+(3)] / release [(2)-(3)] / ~~invocation~~ ~~[(1)-(3)]~~]**	
	Number	% of total share capital	Number	% of total share capital	Type of event (~~creation~~ / Release ~~/ invocation~~)	Date of ~~creation~~ / release/- ~~invocation of encumbrance~~	Type of encumbrance (pledge~~/ line/ non disposal undertaking/ others~~)	Reasons for encumbrance **	Number	% of share capital	Name of the entity in whose favor shares Encumbered ***	Number	% of total share capital
Docon Technologies Private	8,12,00,000	51.02	8,12,00,000	51.02	Release of pledge	August 17, 2026	Release of pledge on 7,94,69,696	The shares were pledged as	Release of pledge on 7,94,69,696	49.93	Docon had outstanding pledge over 7,94,69,696 equity shares of Thyrocare in favour of Catalyst Trusteeship Limited, acting as the Debenture	-	-

<table>
<tr>
<td>Limited
("Docon")</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>equity shares of Thyrocare Technologies Limited held by Docon Technologies Private Limited (Promoter of Thyrocare Technologies Limited), which had been pledged in favour of Catalyst Trusteeship Limited in connection with the existing Non-Convertible Debentures ("NCDs") issued by API Holdings Limited, pursuant to full redemption and</td>
<td>security for the NCDs issued by API Holdings Limited. The outstanding pledge over 7,94,69,696 equity shares was released by Catalyst Trusteeship Limited, acting as Debenture Trustee pursuant to full redemption and repayment of the NCDs.</td>
<td>equity shares of Thyrocare Technologies Limited held by Docon</td>
<td></td>
<td>Trustee, as security for the obligations of API Holdings Limited in respect of the NCDs issued by API.
The aforesaid NCDs, having an outstanding principal amount of INR 10,500 million, were fully redeemed and repaid by API on August 14, 2026. Consequently, upon the full repayment and redemption of the aforesaid NCDs, the pledge created by Docon over 7,94,69,696 equity shares of Thyrocare in favour of Catalyst Trusteeship Limited, acting as the Debenture Trustee, was fully released.
The release of the pledge does not result in any change in Docon's shareholding in Thyrocare. Accordingly, Docon continues to hold 8,12,00,000 equity shares of Thyrocare as on August 17, 2026, representing 51.02% of the total share capital of Thyrocare. Further, no shares held by Docon remain encumbered.

Details of NCD Holders to whom repayment was made:
<table>
<tr><th>Sr</th><th>Name of NCDs Holder</th><th>Principal Amount (INR in Mn)</th></tr>
<tr><td>1</td><td>Poonawalla Fincorp Limited</td><td>918.75</td></tr>
<tr><td>2</td><td>360 One Income Opportunities Fund - Series 7</td><td>131.25</td></tr>
<tr><td>3</td><td>Bagla Industries Private Limited</td><td>21.00</td></tr>
<tr><td>4</td><td>Tata Capital Limited</td><td>2,843.75</td></tr>
</table>
</td>
<td></td>
<td></td>
</tr>
</table>

							repayment of the NCDs.				5	Ganesh Polychem Ltd	43.75		
											6	360 One Prime Limited	4,870.25		
											7	Advik Hi Tech Private Limited	29.75		
											8	Micro Labs Limited	59.50		
											9	Sak Industries Private Ltd	151.38		
											10	Ban Labs Private Limited	55.13		
											11	Lake Chemicals P Ltd	29.75		
											12	Sonnet Trade and Investments Pvt Ltd	9.63		
											13	Vara Future LLP	29.75		
											14	Moorjani Ventures Private Limited	29.75		
											15	Medley Pharmaceuticals Limited	29.75		
											16	Bennett Coleman and Company Limited	437.50		
											17	Urmila Behera	12.25		
											18	Warmond Fiduciary Services Limited	12.25		
											19	Warmond Fiduciary Services Limited	22.75		
											20	Warmond Fiduciary Services Limited	22.75		
											21	Warmond Fiduciary Services Limited	5.25		
											22	Mvs Ventures Private Limited	58.62		
											23	Alkram Venture Private Limited	58.62		
											24	Warmond Fiduciary	17.50		

												Services Limited			
											25	Warmond Fiduciary Services Limited	35.00		
											26	Warmond Fiduciary Services Limited	17.50		
											27	Warmond Fiduciary Services Limited	12.25		
											28	Rajendrakumar Shivkishan Agrawal	87.50		
											29	Harjeet Kohli	26.25		
											30	Pitre Business Ventures LLP	29.75		
											31	Dayanidhi Maran	59.50		
											32	JPM Merchandise Agencies Limited	17.50		
											33	J Kumar Infra projects Limited	314.12		
												Total	**10,500.00**		

For and on behalf of **Docon Technologies Private Limited**

Sd/- Madhuri

Madhuri Sudhir Sarangdhar
Company Secretary
Date: August 17, 2026

Docon Technologies Private Limited

(**) The names of all the promoters, their shareholding in the target company and their pledged shareholding as on the reporting date should appear in the table irrespective of whether they are reporting on the date of event or not.
(*) Total share capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement. Diluted share / voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities / warrants into equity shares of the TC.